Evotec SE Reports Q3 Revenues Down 7.1% to €535.1m, D&PD Revenues Down 12.3% to €392.1m

Evotec SE reported Q3 group revenues of €535.1m, a decrease of 7.1% YoY. Total D&PD revenues fell by 12.3% to €392.1m due to soft demand in the early drug discovery service market. However, quotations are growing, indicating potential future growth.